Glyco-based Vaccine Development

In the future, the demand and complexity of glyco-based vaccines will continue to increase. In order to promote the faster development of glyco-based vaccines, CD BioGlyco has developed a series of outstanding vaccine development platforms by integrating various advanced technologies. We have confidence to be your essential research assistant in the field of glycobiology.

Glyco-based Vaccine Development

Background

Vaccines are one of the most cost-effective interventions to prevent infectious diseases, especially in developing countries where many diseases still need to be controlled. In the past period of time, people have controlled and eliminated many viral and bacterial infectious diseases (such as smallpox, polio, tetanus, etc.) through vaccines, greatly improving the quality of human life.

Saccharides and glycoconjugates are widely distributed on the surface and inside of various types of cells, and play an essential role in many life activities, and abnormal glycosylation patterns have also been found on the surface of tumor cells. Since the first glycoconjugate vaccine against Hib was launched in 1987 and became prevalent, scientists have begun developing glyco- or glycoconjugate-based vaccines for viruses, protozoa, fungi, and cancer.

The development of glycol-based vaccines is a complex process and usually time-consuming. To accelerate their release onto the market and control the economic cost, CD BioGlyco has developed glyco-based vaccine development platforms to provide customers with better solutions for vaccine design, production, and optimization. We will help speed up the vaccine development and preclinical studies and fight new infections and meet unmet medical needs.

Solutions

Advantages of Us

  • Multiple production systems
  • Apply multiple modifications to the products as required
  • Comprehensive vaccine process quality assessment system
  • Design, production, and inspection one-stop service

CD BioGlyco is a biotechnology company highly experienced in develoing glycobiology-related products and services To promote the development of glycomedicine, we have developed a series of technology platforms for glyco-based vaccine, providing customers with comprehensive, high-quality, and affordable services. We have received positive feedback from worldwide scientists for our professionalism and dedication.

Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.

Reference

Micoli, F. et al. Glycoconjugate vaccines: current approaches towards faster vaccine design. Expert Review of Vaccines. 2019: 1-15.

This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.